European patent office yanks Nexium protection

AstraZeneca lost a European patent fight over Nexium, as regulators there invalidated one patent on the stomach drug. Thirteen generics makers had challenged the patent, which also is under review at a trial in the U.K.; the company says it's reviewing its options. Report

Suggested Articles

A $300M pandemic ad campaign may be falling apart as HHS employees push back, celebrities balk and agency brass push a rushed timeline, Politico says.

With a pack of drugmakers angling for COVID-19 vaccine approvals in the coming months, the task of global distribution is more important than ever. Wi

"We have a chance to improve our reputation if we deliver on our purpose to find solutions responsibly," GSK CEO Emma Walmsley said.